Bliss GVS Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE416D01022
NSEID: BLISSGVS
BSEID: 506197

INR

120.00

3.55 (3.05%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 1.46 lacs

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Divi's Lab.

Cipla

Sun Pharma.Inds.

Torrent Pharma

Sigachi Indust.

Lincoln Pharma.

Valiant Organics

Bliss GVS Pharma

Themis Medicare

Mankind Pharma

Remus Pharma.

Why is Bliss GVS Pharma Ltd ?

Poor long term growth as Net Sales has grown by an annual rate of -0.09% and Operating profit at -3.73% over the last 5 years

Negative results in Dec 24

INTEREST(HY) At Rs 4.91 cr has Grown at 45.27 %
PBT LESS OI(Q) At Rs 21.15 cr has Fallen at -38.91 %
PAT(HY) At Rs 48.06 cr has Grown at -31.26 %

Stock is technically in a Bearish range

The technical trend has deteriorated from Sideways on 07-Apr-25 and has generated 2.56% returns since then
Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Bliss GVS Pharma for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Bliss GVS Pharma

4.48%

0.08

54.31%

SENSEX

0.45%

0.03

14.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.09%

EBIT Growth (5y)

-3.73%

EBIT to Interest (avg)

14.67

Debt to EBITDA (avg)

0.89

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.73

Tax Ratio

30.09%

Dividend Payout Ratio

6.94%

Pledged Shares

Institutional Holding

20.06%

ROCE (avg)

12.76%

ROE (avg)

9.43%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.22

EV to EBIT

10.42

EV to EBITDA

8.22

EV to Capital Employed

1.25

EV to Sales

1.36

PEG Ratio

13.82

Dividend Yield

0.43%

ROCE (Latest)

13.60%

ROE (Latest)

9.17%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

DEBT-EQUITY RATIO(HY)

Lowest at 0.09 times

OPERATING PROFIT TO INTEREST(Q)

Highest at 27.58 times

CASH AND CASH EQUIVALENTS(HY)

Highest at Rs 219.84 cr

-12What is not working for the Company

INTEREST(HY)

At Rs 4.91 cr has Grown at 45.27 %

PBT LESS OI(Q)

At Rs 21.15 cr has Fallen at -38.91 %

PAT(HY)

At Rs 48.06 cr has Grown at -31.26 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.87 times

OPERATING PROFIT TO NET SALES (Q)

Lowest at 14.16%

NON-OPERATING INCOME(Q)

is 41.93 % of Profit Before Tax (PBT

Loading Valuation Snapshot...

Here's what is working for Bliss GVS Pharma

Operating Profit to Interest - Quarterly

Highest at 27.58 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Debt-Equity Ratio - Half Yearly

Lowest at 0.09 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Cash and Cash Equivalents - Half Yearly

Highest at Rs 219.84 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Bliss GVS Pharma

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 21.15 cr has Fallen at -38.91 %

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Interest - Half Yearly

At Rs 4.91 cr has Grown at 45.27 %

over previous Half yearly period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Profit After Tax (PAT) - Half Yearly

At Rs 48.06 cr has Grown at -31.26 %

Year on Year (YoY)

MOJO Watch

Near term PAT trend is negative

PAT (Rs Cr)

Operating Profit Margin - Quarterly

Lowest at 14.16%

in the last five quarters

MOJO Watch

Company's efficiency has deteriorated

Operating Profit to Sales

Non Operating Income - Quarterly

is 41.93 % of Profit Before Tax (PBT)

MOJO Watch

The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT

Debtors Turnover Ratio- Half Yearly

Lowest at 1.87 times

in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio

Non Operating Income - Quarterly

Highest at Rs 15.27 cr

in the last five quarters

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating Income